Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained

BioDrugs

Volumn 32, Issue 2, 2018, Pages 129-135

  Aapro, Matti ^a   Krendyukov, Andriy ^b   Schiestl, Martin ^c   Gascón, Pere ^d  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b Sandoz Pharma Ltd   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT;

BIOLOGICAL THERAPY; CHEMOTHERAPY INDUCED ANEMIA; DRUG INDICATION; DRUG QUALITY; DRUG SAFETY; EUROPEAN; EUROPEAN MEDICINES AGENCY; HUMAN; IMMUNOGENICITY; PERSONAL EXPERIENCE; PRIORITY JOURNAL; REVIEW; ANEMIA; CHEMICALLY INDUCED; EUROPE; IMMUNOLOGY;

ANEMIA; ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; EPOETIN ALFA; EUROPE; HUMANS;

EID: 85041534797     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-018-0262-9     Document Type: Review

References (43)

1. Aapro M. Biosimilars in oncology: current and future perspectives. GaBI J. 2013;2:91–3.
2. Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15:e594–605.
3. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2016;1:e000142.
4. European Medicines Agency (EMA). Guideline on similar biological medicinal products. European Medicines Agency. 2005. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed 15 Jun 2017.
5. European Medicines Agency (EMA). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). European Medicines Agency. 2010. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf. Accessed 15 Jun 2017.
6. Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist. 2004;9:97–107.
7. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7.
8. Curigliano G, O’Connor DP, Rosenberg JA, Jacobs I. Biosimilars: extrapolation for oncology. Crit Rev Oncol Hematol. 2016;104:131–7.
9. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol. 2010;28:28–31.
10. Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28:386–93.
11. Halim LA, Brinks V, Jiskoot W, Romeijn S, Haselberg R, Burns C, Wadhwa M, Schellekens H. Quality and batch-to-batch consistency of original and biosimilar epoetin products. J Pharm Sci. 2016;105:542–50.
12. Covic A, Abraham I. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. Int Urol Nephrol. 2015;47:1529–39.
13. European Medicines Agency (EMA). Binocrit, INN-epoetin alfa: scientific discussion. European Medicines Agency. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdf. Accessed 15 Jun 2017.
14. Mikhail A, Farouk M. Epoetin biosimilars in Europe: five years on. Adv Ther. 2013;30:28–40.
15. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124:3191–6.
16. Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica. 2011;96:942–7.
17. Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, Pane F, Tura S. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011;96:937–42.
18. Danese S, Gomollon F, Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7:586–9.
19. Fonseca JE, Gonçalves J, Araújo F, Cordeiro I, Teixeira F, Canhão H, da Silva JA, Garcês S, Miranda LC, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port. 2014;39:60–71.
20. Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I, SIR, SIDeMaST, IG-IBD. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014;13:751–5.
21. Mularczyk A, Gonciarz M, Bartnik W, Durlik M, Eder P, Gąsiorowska A, Linke K, Łodyga M, Łykowska-Szuber L, et al. Biosimilar medicines—their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Prz Gastroenterol. 2014;9:1–3.
22. European Medicines Agency (EMA). Retacrit, INN-epoetin zeta: scientific discussion. European Medicines Agency. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000872/WC500054374.pdf. Accessed 15 Jun 2017.
23. Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2012;77:8–17.
24. Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454–67.
25. Casadevall N, Dobronravov V, Eckardt KU, Ertürk S, Martynyuk L, Schmitt S, Schaffar G, Rudy A, Krendyukov A, Ode M. Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anaemia associated with chronic kidney disease in pre-dialysis and dialysis patients. Clin Nephrol. 2017;88:190–7.
26. Panichi V, Ricchiuti G, Scatena A, Del Vecchio L, Locatelli F. Pure red cell aplasia by epoetin zeta. Clin Kidney J. 2016;9:599–602.
27. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80:88–92.
28. Leung LK, Mok K, Liu C, Chan SL. What do oncologists need to know about biosimilar products? Chin J Cancer. 2016;35:91.
29. Hörl WH, Locatelli F, Haag-Weber M, Ode M, Roth K, Epo-PASS study group. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10–12 g/dl. Clin Nephrol. 2012;78:24–32.
30. Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe LM, Labourey JL, Lepille D, et al. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. BMC Cancer. 2014;14:503.
31. Michallet M, Losem C. Biosimilar epoetin zeta in oncology and haematology: development and experience following 6 years of use. Acta Haematol. 2016;135:44–52.
32. Trotta F, Belleudi V, Fusco D, Amato L, Mecozzi A, Mayer F, Sansone M, Davoli M, Addis A. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open. 2017;7:e011637.
33. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12:1473–85.
34. D’Amore C, Da Cas R, Rossi M, Traversa G. Switching between epoetins: a practice in support of biosimilar use. BioDrugs. 2016;30:27–32.
35. Minutolo R, Borzumati M, Sposini S, Abaterusso C, Carraro G, Santoboni A, Mura C, Filiberti O, Santoro D, et al. Dosing penalty of erythropoiesis-stimulating agents after switching from originator to biosimilar preparations in stable hemodialysis patients. 2016;68:170–2.
36. Hörbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol. 2013;69:929–36.
37. Generics and Biosimilars Initiative (GaBI). Biosimilars approved in Europe. Generics and Biosimilars Initiative. 2016. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed 15 Jun 2017.
38. Wish JB, Charytan C, Chertow GM, Kalantar-Zadeh K, Kliger AS, Rubin RJ, Yee J, Fishbane S. Introduction of biosimilar therapeutics into nephrology practice in the United States: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis. 2016;68:843–52.
39. US Food and Drug Administration (FDA). Biosimilars: biosimilarity guidelines. US Food and Drug Administration. Nov 2015. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm290967.htm. Accessed 15 Jun 2017.
40. Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31:83–91.
41. US Food and Drug Administration (FDA). Press announcements: FDA approves first biosimilar product Zarxio. US Food and Drug Administration. 6 Mar 2015. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm436648.htm. Accessed 15 Jun 2017.
42. US Food and Drug Administration (FDA). FDA briefing document: BLA 125545 “Epoetin Hospira”, a proposed biosimilar to Epogen/Procrit (epoetin alfa). 2017. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM559967.pdf. Accessed 15 Jun 2017.
43. US Food and Drug Administration (FDA). Information on erythropoiesis-stimulating agents (ESA) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp). US Food and Drug Administration. 2017. https://www.fda.gov/Drugs/DrugSafety/ucm109375.htm. Accessed 15 Jun 2017.